Letter to the Editor Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/Pharmacol.3.024
Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis
Vijairam Selvaraj1,2,*, Karl Herman1,2, Arkadiy Finn1,2, Atin Jindal1,2, Kwame Dapaah-Afriyie1,2
- 1Division of Hospital Medicine, The Miriam Hospital, Providence, Rhode Island, USA
- 2Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
Corresponding Author
Vijairam Selvaraj, vijairam.selvaraj@lifespan.org
Received Date: April 03, 2021
Accepted Date: May 03, 2021
Selvaraj V, Herman K, Finn A, Jindal A, Dapaah-Afriyie K. Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis. Arch Pharmacol Ther. 2021; 3(2):29-31.
Copyright: © 2021 Selvaraj V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
To date, only glucocorticoids have been shown to reduce mortality in COVID-19. Use of remdesivir was associated with reduced length of stay in hospitalized COVID-19 patients. A deadly second wave in Asian countries has caused increased demand and usage of remdesivir in these countries. However, there is limited data about its efficacy in patients with severe renal dysfunction or end-stage renal disease on dialysis.
Recommended Articles
Karyotypic Profile of Chronic Myeloid Leukemia in Patients Diagnosed at Tertiary Level in Afghanistan
Balanced translocation resulting in fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2 is the pathognomonic molecular driver of CML. The resulting BCRABL 1 fusion gene is both the diagnostic as well as therapeutic target of CML. The first agent with tyrosine kinase inhibitor activity that was licenced in 2000 for treatment of CML patients, was Imatinib, gradually followed by multiple agents with higher efficacy.
Prevalence of Symptom Clusters in Cancer Patients at First Presentation in Palliative Care Clinic as per Different Disease Groups
Cancer has its own disease burden and patients usually suffer from symptom clusters when they are referred for palliative treatment. Identification of symptom cluster trajectories will help clinician to take into account measures that can optimize quality of life of palliative patients. Therefore the aim of this paper is to determine the overall prevalence of symptoms and symptoms clusters in different disease groups according to etiology at the time of first visit to Palliative care clinic by using HIS Palliative First Assessment note indicating Edmonton symptom scale.
COVID-19 Clinical Research
While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency.
Therapeutic Values of Ketamine for COVID-19-Cared Patients: An Expert’s Point of View
Ketamine has long been used in the field of anesthesia [1]. Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.
A Bioinformatics Protocol for Rational Design of Peptide Vaccines and the COVID-19 Rampage
The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.